Adenovirus type 5 (Ad5) has been intensively studied as a viral vector for gene therapy, and understanding host–Ad5 interactions will be key to the safe and effective use of this vector. A recent study in mice provides new insights in this area by showing that Ad5 enlists a host coagulation factor to overcome complement-mediated blockade and infect the liver (pages 452–457).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari
References
Raper, S.E. et al. Mol. Genet. Metab. 80, 148–158 (2003).
Xu, Z. et al. Nat. Med. 19, 452–457 (2013).
Wickham, T.J. et al. Cell 73, 309–319 (1993).
Kalyuzhniy, O. et al. Proc. Natl. Acad. Sci. USA 105, 5483–5488 (2008).
Waddington, S.N. et al. Cell 132, 397–409 (2008).
Shayakhmetov, D.M. et al. J. Virol. 79, 7478–7491 (2005).
Smith, T.A. et al. Hum. Gene Ther. 14, 777–787 (2003).
Cooper, N.R. & Nemerow, G.R. Springer Semin. Immunopathol. 6, 327–347 (1983).
Xu, Z. et al. J. Virol. 82, 11705–11713 (2008).
Khare, R. et al. J. Virol. 86, 2293–2301 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Nemerow, G. Coagulation factor defends adenovirus from immune attack. Nat Med 19, 406–407 (2013). https://doi.org/10.1038/nm.3149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3149
